TGF-β signaling in vascular fibrosis

Cardiovascular Research

Volumn 74, Issue 2, 2007, Pages 196-206

  Ruiz Ortega, Marta ^a   Rodríguez Vita, Juan ^a   Sanchez Lopez, Elsa ^a   Carvajal, Gisselle ^a   Egido, Jesús ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Angiotensin; Fibrosis; MAPK kinases; Signal transduction; Smooth muscle

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANTIFIBROTIC AGENT; CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN CDC42; PROTEIN KINASE; RAC PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHO FACTOR; SERUM RESPONSE FACTOR; SMAD PROTEIN; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD5 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; SMAD8 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL GROWTH; DRUG EFFICACY; EXTRACELLULAR MATRIX; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; VASCULAR FIBROSIS;

ANIMALS; FIBROSIS; HEART DISEASES; HUMANS; MUSCLE, SMOOTH, VASCULAR; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 34047156556     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2007.02.008     Document Type: Review

References (83)

1. Massague J., Seoane J., and Wotton D. Smad transcription factors. Genes Dev 19 (2005) 2783-2810
2. Javelaud D., and Mauviel A. Mammalian transforming growth factor-betas: Smad signaling and physiopathological roles. Int J Biochem Cell Biol 36 (2004) 1161-1165
3. Moustakas A., Pardali K., Gaal A., and Heldin C.H. Mechanisms of TGF-β signaling in regulation of cell growth and differentiation. Immunol Lett 82 (2002) 85-91
4. Annes J.P., Munger J.S., and Rifkin D.B. Making sense of latent TGFbeta activation. J Cell Sci 116 (2003) 217-224
5. Leask A., and Abraham D.J. TGF-β signaling and the fibrotic response. FASEB J 18 (2004) 816-817
6. Gibbons G.H., Pratt R.E., and Dzau V.J. Vascular smooth muscle cell hypertrophy vs. Hyperplasia. Autocrine transforming growth factor-β1 expression determines growth responses to angiotensin. J Clin Invest 90 (1992) 456-461
7. Weigert C., Brodbeck K., Klopfer K., Häring H.U., and Schleicher E.D. Angiotensin II induces human TGF-β1 promoter activation: similarity to hyperglycaemia. Diabetologia 45 (2002) 890-898
8. Naito T., Masaki T., Nikolic-Paterson D.J., Tanji C., Yorioka, and Kohno N. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-β1. Am J Physiol Renal Physiol 286 (2004) F278-F287
9. Wang M., Zhao D., Spinetti G., Zhang J., Jiang L.Q., Pintus G., et al. Matrix metalloproteinase 2 activation of transforming growth factor-β1 (TGF-β) and TGF-β1-type II receptor signaling within the aged arterial wall. Arterioscler Thromb Vasc Biol 26 (2006) 1503-1509
10. Song C.Y., Kim B.C., Hong H.K., and Lee H.S. Oxidized LDL activates PAI-1 transcription through autocrine activation of TGF-β signaling in mesangial cells. Kidney Int 67 (2005) 1743-1752
11. Berk B.C. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev 81 3 (2001) 999-1030
12. Zegarska J., Paczek L., Pawlowska M., Wyczalkowska A., Michalska W., Ziolkowski J., et al. Increased mRNA expression of transforming growth factor beta in the arterial wall of chronically rejected renal allografts in humans. Transplant Proc 38 (2006) 115-118
13. Ryan S.T., Koteliansky V.E., Gotwals P.J., and Lindner V. Transforming growth factor-beta-dependent events in vascular remodeling following arterial injury. J Vasc Res 40 (2003) 37-46
14. Grainger D.J. Transforming growth factor-b and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 24 (2004) 399-404
15. Grainger DJ. TGF-β and Atherosclerosis in Man. Cardiovasc Res in press (Accepted Manuscript, Available online 23 February 2007).
16. Euler-Taimor G., and Heger J. The complex pattern of SMAD signaling in the cardiovascular system. Cardiovasc Res 69 (2006) 15-25
17. Khan R., and Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 118 (2006) 10-14
18. Zacchigna L., Vecchione C., Notte A., Cordenonsi M., Dupont S., Maretto S., et al. Emilin 1 links TGF-β maturation to blood pressure homeostasis. Cell 124 (2006) 929-932
19. Dai J., Losy F., Guinault A.M., Pages C., Anegon I., Desgranges P., et al. Overexpression of transforming growth factor-beta1 stabilizes already-formed aortic aneurysms: a first approach to induction of functional healing by endovascular gene therapy. Circulation 112 7 (2005) 1008-1015
20. Loeys B.L., Schwarze U., Holm T., Callewaert B.L., Thomas G.H., Pannu H., et al. Aneurysm syndromes caused by mutations in the TGF-β receptor. N Engl J Med 355 (2006) 788-798
21. Habashi J.P., Judge D.P., Holm T.M., Cohn R.D., Loeys B.L., Cooper T.K., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312 5770 (2006) 117-121
22. Verrecchia F., and Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 118 (2002) 211-215
23. Ruiz-Ortega M., Ruperez M., Esteban V., and Egido J. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 5 (2003) 73-79
24. Li J.H., Huang X.R., Zhu H.J., Johnson R., and Lan H.Y. Role of TGF-β signaling in extracellular matrix production under high glucose conditions. Kidney Int 63 (2003) 2010-2019
25. Li J.H., Huang X.R., Zhu H.J., Oldfield M., Cooper M., Truong L.D., et al. Advanced glycation end products activate Smad signaling via TGF-β-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 18 (2004) 176-178
26. Roberts A.B. TGF-β signaling from receptors to the nucleus. Microbes Infect 1 (1999) 1265-1273
27. Graham H., and Peng C. Activin receptor-like kinases: structure, function and clinical implications. Endocr Metab Immune Disord Drug Targets 6 (2006) 45-58
28. Lebrin F., Deckers M., Bertolino P., and Ten Dijke P. TGF-β receptor function in the endothelium. Cardiovasc Res 65 (2005) 599-608
29. Seki T., Hong K.H., and Oh S.P. Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development. Lab Invest 86 (2006) 116-119
30. Koleva R.I., Conley B.A., Romero D., Riley K.S., Marto J.A., Lux A., et al. Endoglin structure and function: determinants of endoglin phosphorylation by TGFbeta receptors. J Biol Chem 281 (2006) 25110-25119
31. Fonsatti E., Del Vecchio L., Altomonte M., Sigalotti L., Nicotra M.R., Coral S., et al. Endoglin: an accessory component of the TGF-β-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 188 (2001) 1-7
32. Bernard D.J., Chapman S.C., and Woodruff T.K. Inhibin binding protein (InhBP/p120), betaglycan, and the continuing search for the inhibin receptor. Mol Endocrinol 16 (2002) 207-212
33. Nakao A., Okumura K., and Ogawa H. Smad7: a new key player in TGF-β-associated disease. Trends Mol Med 8 (2002) 361-363
34. Ikedo H., Tamaki K., Ueda S., Kato S., Fujii M., Ten Dijke P., et al. Smad protein and TGF-β signaling in vascular smooth muscle cells. Int J Mol Med 11 (2003) 645-650
35. Rodriguez-Vita J., Sanchez-Lopez E., Esteban V., Ruperez M., Egido J., and Ruiz-Ortega M. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 111 (2005) 2509-2517
36. Wang W., Huang X.R., Canlas E., Oka K., Truong L.D., Deng C., et al. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 98 (2006) 1032-1039
37. Wang T. The 26S proteasome system in the signaling pathways of TGF-β superfamily. Front Biosci 8 (2003) 1109-1117
38. Berg D.T., Myers L.J., Richardson M.A., Sandusky G., and Grinnell B.W. Smad6s regulates plasminogen activator inhibitor-1 through a protein kinaseC-beta-dependent up-regulation of transforming growth factor-beta. J Biol Chem 280 (2005) 14943-14947
39. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425 (2003) 577-584
40. Isono M., Chen S., Hong S.W., Iglesias-de la Cruz M.C., and Ziyadeh F.N. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-β-induced fibronectin in mesangial cells. Biochem Biophys Res Commun 296 (2002) 1356-1365
41. Dennler S., Itoh S., Vivien D., ten Dijke P., Huet S., and Gauthier J.M. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17 (1998) 3091-3100
42. Chen S.J., Yuan W., Lo S., Trojanowska M., and Varga J. Interaction of smad3 with a proximal smad-binding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-β. J Cell Physiol 183 (2000) 381-382
43. Ryer E.J., Hom R.P., Sakakibara K., Nakayama K.I., Nakayama K., Faries P.L., et al. PKCdelta is necessary for Smad3 expression and transforming growth factor beta-induced fibronectin synthesis in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2006) 26780-26786
44. Mallawaarachchi C.M., Weissberg P.L., and Siow R.C. Smad7 gene transfer attenuates adventitial cell migration and vascular remodeling after balloon injury. Arterioscler Thromb Vasc Biol 25 (2005) 1383-1387
45. Nomura M., and Li E. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature (London) 393 (1998) 786-790
46. Zhu Y., Richardson J.A., Parada L.F., and Graff J.M. Smad3 mutant mice develop metastatic colorectal cancer. Cell 94 (1998) 703-704
47. Yang Y.C., Piek E., Zavadil J., Liang D., Xie D., Heyer J., et al. Hierarchical model of gene regulation by transforming growth factor beta. Proc Natl Acad Sci U S A 100 (2003) 10269-10274
48. Kobayashi K., Yokote K., Fujimoto M., Yamashita K., Sakamoto A., Kitahara M., et al. Targeted disruption of TGF-β-Smad3 signaling leads to enhanced neointimal hyperplasia with diminished matrix deposition in response to vascular injury. Circ Res 96 (2005) 904-912
49. Kalinina N., Agrotis A., Antropova Y., Ilyinskaya O., Smirnov V., Tararak E., et al. Smad expression in human atherosclerotic lesions: evidence for impaired TGF-β/Smad signaling in smooth muscle cells of fibrofatty lesions. 1. Arterioscler Thromb Vasc Biol 24 (2004) 1391-1396
50. Hayashida T., deCasestecker M., and Schnaper H.W. Cross-talk between ERK MAP kinase and Smad-signaling pathways enhances TGF-β dependent responses in human mesangial cells. FASEB J 17 (2003) 1576-1578
51. Seay U., Sedding D., Krick S., Hecker M., Seeger W., and Eickelberg O. Transforming growth factor-beta-dependent growth inhibition in primary vascular smooth muscle cells is p38-dependent. J Pharmacol Exp Ther 315 (2005) 1005-1012
52. Samarakoon R., Higgins C.E., Higgins S.P., Kutz S.M., and Higgins P.J. Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-β1-stimulated smooth muscle cells is pp60(c-src)/MEK-dependent. J Cell Physiol 204 (2005) 236-246
53. Van Aelst L., and D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 11 (1997) 2295-2322
54. Deaton R.A., Su C., Valencia T.G., and Grant S.R. Transforming growth factor-beta1-induced expression of smooth muscle marker genes involves activation of PKN and p38 MAPK. J Biol Chem 280 (2005) 31172-31181
55. Chen S., Crawford M., Day R.M., Briones V.R., Leader J.E., Jose P.A., et al. RhoA modulates Smad signaling during transforming growth factor-beta-induced smooth muscle differentiation. J Biol Chem 281 (2006) 1765-1770
56. Nishimura G., Manabe I., Tsushima K., Fujiu K., Oishi Y., Imai Y., et al. DeltaEF1 mediates TGF-β signaling in vascular smooth muscle cell differentiation. Dev Cell 11 (2006) 93-94
57. Ruperez M., Sanchez-Lopez E., Blanco-Colio L.M., Esteban V., Rodriguez-Vita J., Plaza J.J., et al. The Rho-kinase pathway regulates angiotensin II-induced renal damage. Kidney Int Suppl 99 (2005) S39-S45
58. Kataoka C., Egashira K., Inoue S., Takemoto M., Ni W., Koyanagi M., et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 39 (2002) 245-250
59. Nishikimi T., Akimoto K., Wang X., Mori Y., Tadokoro K., Ishikawa Y., et al. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. Hypertens 22 (2004) 1787-1796
60. Hong Y.H., Peng H.B., La Fata V., and Liao J.K. Hydrogen peroxide-mediated transcriptional induction of macrophage colony-stimulation factor by TGF-β1. J Immunol 159 (1997) 2418-2423
61. Koo H.Y., Shin I., Lee Z.W., Lee S.H., Kim S.H., Lee C.H., et al. Roles of RhoA and phospholipase A2 in the elevation of intracellular H2O2 by transforming growth factor-b in Swiss 3T3 fibroblasts. Cell Signal 11 (1999) 677-683
62. Jiang Z., Seo J.Y., Ha H., Lee E.A., Kim Y.S., Han D.C., et al. Reactive oxygen species mediate TGF-β1-induced plasminogen activator inhibitor-1 upregulation in mesangial cells. Biochem Biophys Res Commun 309 (2003) 961-966
63. Sturrock A., Cahill B., Norman K., Huecksteadt T.P., Hill K., Sanders K., et al. Transforming growth factor-beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 290 (2006) L661-L663
64. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 363 (2004) 62-64
65. Oemar B.S., Werner A., Garnier J.M., Do D.D., Godoy N., Nauck M., et al. Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation 18 (1997) 831-839
66. Chen M.M., Lam A., Abraham J.A., Schreiner G.F., and Joly A.H. CTGF expression is induced by TGF-β in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 32 (2000) 1805-1809
67. Finckenberg P., Lassila M., Inkinen K., Pere A.K., Krogerus L., Lindgren L., et al. Cyclosporine induces myocardial connective tissue growth factor in spontaneously hypertensive rats on high-sodium diet. Transplantation 71 (2001) 951-958
68. Ruperez M., Lorenzo O., Blanco-Colio L.M., Esteban V., Egido J., and Ruiz-Ortega M. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 108 (2003) 1499-1505
69. Fan W.H., Pech M., and Karnovsky M.J. Connective tissue growth factor (CTGF) stimulates vascular smooth muscle cell growth and migration in vitro. Eur J Cell Biol 79 (2000) 915-923
70. Rodriguez-Vita J., Ruiz-Ortega M., Ruperez M., Esteban V., Sanchez-Lopez E., Plaza J.J., et al. Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res 97 (2005) 125-134
71. Abreu J.G., Ketpura N.I., Reversade B., and De Robertis E.M. Connective-tissue growth factor (CTGF) modulates Cell Signalling by BMP and TGF-β. Nat Cell Biol 4 (2002) 599-604
72. Wahab N.A., Weston B.S., and Mason R.M. Modulation of the TGF-β/Smad signaling pathway in mesangial cells by CTGF/CCN2. Exp Cell Res 307 (2005) 305-314
73. Kulkarni A.B., Huh C.G., Becker D., Geiser A., Lyght M., Flanders K.C., et al. Transforming growth factor-b1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 15 (1993) 770-774
74. Ivkovic S., Yoon B.S., Popoff S.N., Safadi F.F., Libuda D.E., Stephenson R.C., et al. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 130 (2003) 2779-2781
75. Tuñon J., Ruiz-Ortega M., and Egido J. Regulation of matrix proteins and impact on vascular structure. Curr Hypertens Rep 2 (2000) 106-113
76. Hao J., Wang B., Jones S.C., Jassal D.S., and Dixon I.M. Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol Heart Circ Physiol 279 (2000) H3020-H3030
77. Carvajal G., Ruperez M., Sanchez-Lopez E., Rodriguez-Vita J., Rodrigues-Diez R., Esteban V., et al. Angiotensin II causes epithelial mesenchymal transdifferentiation via activation of Smad and MAPK signaling pathways. Nephrol Dial 21 (2006) 289 [Abstract]
78. Wamsley-Davis A., Padda R., Truong L.D., Tsao C.C., Zhang P., and Sheikh-Hamad D. AT1A-mediated activation of kidney JNK1 and SMAD2 in obstructive uropathy: Preservation of kidney tissue mass using Candesartan. Am J Physiol Renal Physiol 287 (2004) F474-F480
79. Ruiz-Ortega M., Ruperez M., Esteban V., Rodriguez-Vita J., Sanchez-Lopez E., Carvajal G., et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 21 (2006) 16-20
80. Paravicini T.M., and Touyz R.M. Redox signaling in hypertension. Cardiovasc Res 71 (2006) 247-258
81. Fanayan S., Firth S.M., Butt A.J., and Baxter R.C. Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-β (TGF-β) and the type II TGF-β receptor. J Biol Chem 275 (2000) 39146-39151
82. Lutz M., Krieglstein K., Schmitt S., ten Dijke P., Sebald W., Wizenmann A., et al. Nerve growth factor mediates activation of the Smad pathway in PC12 cells. Eur J Biochem 271 (2004) 920-921
83. Seoane J. Escaping from the TGF-β anti-proliferative control. Carcinogenesis 27 (2006) 2148-2156